Increased midgestational IFN-γ, IL-4 and IL-5 in women bearing a child with autism: A case-control study
© Goines et al; licensee BioMed Central Ltd. 2011
Received: 1 February 2011
Accepted: 2 August 2011
Published: 2 August 2011
Immune anomalies have been documented in individuals with autism spectrum disorders (ASDs) and their family members. It is unknown whether the maternal immune profile during pregnancy is associated with the risk of bearing a child with ASD or other neurodevelopmental disorders.
Using Luminex technology, levels of 17 cytokines and chemokines were measured in banked serum collected from women at 15 to 19 weeks of gestation who gave birth to a child ultimately diagnosed with (1) ASD (n = 84), (2) a developmental delay (DD) but not autism (n = 49) or (3) no known developmental disability (general population (GP); n = 159). ASD and DD risk associated with maternal cytokine and chemokine levels was estimated by using multivariable logistic regression analysis.
Elevated concentrations of IFN-γ, IL-4 and IL-5 in midgestation maternal serum were significantly associated with a 50% increased risk of ASD, regardless of ASD onset type and the presence of intellectual disability. By contrast, elevated concentrations of IL-2, IL-4 and IL-6 were significantly associated with an increased risk of DD without autism.
The profile of elevated serum IFN-γ, IL-4 and IL-5 was more common in women who gave birth to a child subsequently diagnosed with ASD. An alternative profile of increased IL-2, IL-4 and IL-6 was more common for women who gave birth to a child subsequently diagnosed with DD without autism. Further investigation is needed to characterize the relationship between these divergent maternal immunological phenotypes and to evaluate their effect on neurodevelopment.
Autism spectrum disorders (ASDs) are a heterogeneous group of neurodevelopmental diseases that manifest in early childhood. Individuals with ASD demonstrate varying degrees of social impairments, deficits in language and communication and stereotypic and repetitive behaviors . There are no clear biological markers for ASD, and current diagnosis relies entirely on behavioral criteria [2, 3]. Little is known about the pathology and etiology of the disorders, though genetic, neurologic, environmental and/or immune factors are likely involved . Recent epidemiologic data suggest that approximately 1 in 100 children is diagnosed with an ASD [5, 6], highlighting the urgent need for better understanding of this complex disorder.
Evidence has linked various types of maternal immune activation and dysregulation to behavioral disorders, including ASD [7, 8]. Mothers of children with ASD have been reported to have a higher incidence of allergic and autoimmune diseases compared to mothers of typically developing children [9–11]. Furthermore, some mothers harbor circulating antibodies that can bind to brain proteins [12–15]. Prenatal immune challenge, such as a bacterial or viral infection, has also been related to behavioral disorders in offspring in both epidemiological studies and animal models . Murine models have shown that exposure to influenza , lipopolysaccharide (LPS)  and polyinosinic:polycytidylic acid (poly(I:C)) [17, 19] during pregnancy results in offspring with altered behavioral phenotypes and brain histopathology, which may be related to aspects of ASD.
The impact of maternal immune activation on the fetal compartment is mediated in part by cytokines and chemokines [7, 18, 19]. Cytokines and chemokines are proteins that control the intensity, duration and type of immune response. Prenatal exposure to altered levels of cytokines such as IL-2  and IL-6  is sufficient to induce learning disabilities and behavioral changes in murine offspring. Maternal cytokines may affect the fetal compartment directly, as IL-6 has been shown to cross the human placenta (unlike many other cytokines) , or indirectly through stimulation of placental cells, which may alter the placental environment and thereby impact the fetus .
Few studies have examined midgestational cytokine levels in mothers and ensuing behavioral outcomes in children. We conducted a case-control study using archived maternal blood samples collected during the period from 15 to 19 weeks of gestation to investigate the potential association between serum cytokine profiles and the risk of bearing a child subsequently diagnosed with a neurodevelopmental disorder. We demonstrate the presence of divergent cytokine profiles in serum taken during the second trimester of pregnancy from mothers bearing (1) a child with ASD, (2) a child with a developmental delay (DD) other than ASD or (3) a child from the general population with no known developmental deficiencies (GP).
The study sample was based on the Early Markers for Autism (EMA) Study. The EMA Study is a population-based, nested case-control study designed to evaluate biologic markers of susceptibility and exposure in archived maternal midpregnancy and neonatal blood specimens from the same mother-baby pairs. The study subjects are women residing in Orange County, California, who were pregnant in 2000 and 2001 and enrolled in the state's Prenatal Expanded AFP Screening Program . Briefly, three groups were identified: mothers of children with autism spectrum disorder (ASD), mothers of children with DD but not ASD and mothers of GP children. Children with ASD or DD were ascertained from client records obtained from the Regional Center of Orange County. This is one of the 21 regional centers operated by the California Department of Developmental Services (DDS), which are designed to coordinate services for persons with autism and other developmental disabilities. Clients receiving DDS services for ASD or suspected ASD were ascertained as possible subjects for inclusion in this study. Other subjects with moderate to profound developmental disabilities but not ASD (specifically children with an IQ <70 based on standardized tests) were ascertained as other possible DD cases. Diagnoses were confirmed by expert review of all ASD and DD cases as described in the next subsection. GP controls were randomly sampled from the birth certificate files and frequency-matched to ASD cases by sex, birth month and birth year at a 2:1 ratio. All past or current DDS/regional center clients were excluded from the GP population. All study procedures were approved by the institutional review boards of the California Health and Human Services Agency and Kaiser Permanente Northern California.
Classification of autism cases in the Early Markers for Autism studya
Autism spectrum disorder subgroups
Number of subjects
Maternal midpregnancy serum specimens were retrieved from the Project Baby's Breath prenatal screening specimen archive maintained by the California Genetic Disease Screening Program, at the California Department of Public Health. As part of the screening program, venous blood was collected at 15 to 19 weeks' gestation in serum separator tubes by obstetrical care service providers and underwent expanded α-fetoprotein screening at a single regional laboratory, typically within seven days of collection (median time = 3 days). During transit via the US Postal Service to the regional screening laboratory, no effort was made to control the temperature of the specimens. After testing, leftover specimens were kept under refrigeration for 1 to 2 days and then stored at -20°C. Aliquots of the samples used for this study were stored at -80°C until use with no freeze-thaws prior to testing. All samples were exposed to the same collection and storage protocols.
Serum concentrations of 17 cytokines and chemokines, including eotaxin, granulocyte macrophage colony-stimulating factor (GM-CSF), IFN-γ, IL-10, IL-12, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IFN-γ-induced protein 10, macrophage inflammatory protein (MIP)-1α, MIP-1β, RANTES and TNF-α were determined using a commercially available multiplex bead-based kit (BioSource Human Bead Kit; Invitrogen, Carlsbad, CA, USA). The assay was carried out in accordance with the protocols provided by the manufacturer. Briefly, 50 μL of serum was incubated with anti-cytokine-conjugated beads in a 96-well filter-bottomed plate on a plate shaker. After two hours, the beads were washed using a vacuum manifold, and biotin-conjugated detection antibodies were added for one-hour incubation. Following a repeat of the washing step, beads were incubated with streptavidin phycoerythrin for 30 minutes. The plates were then read on a Bio-Plex 100 system (Bio-Rad Laboratories, Hercules, CA, USA) and analyzed using Bio-Plex Manager software (Bio-Rad Laboratories) with a five-point standard curve. Reference samples were run on each plate to determine assay consistency.
The distribution of the cytokine concentration values was skewed, and natural log transformation was used to approximate normality. To examine the association of cytokine levels with developmental outcomes after adjustment for possible confounders, we fit separate logistic regression models for ASD vs. GP, ASD vs. DD and DD vs. GP. Case vs. control status was regressed on natural log-transformed cytokine levels with adjustment for several covariates related to the maternal blood draw (maternal weight and gestational age at time of draw) or associated with autism in previous epidemiologic studies (maternal age, race, ethnicity and country of origin). Separate models were run for each cytokine. For all cytokine values that were below the limit of detection (LOD), we assigned a value of LOD/2 prior to log transformation. Fisher's exact tests were used to determine whether there were differences between groups in the proportion of subjects falling within the LOD for each cytokine. Finally, the correlation of individual cytokine levels was tested separately for cases and controls on the basis of the Pearson correlation coefficient.
Characteristics of the Early Markers for Autism study populationa
ASD (N= 84)
DD (N= 49)
GP (N= 159)
ASD vs. GP
ASD vs. DD
DD vs. GP
Mother's birth country
Mean maternal age, years (±SD)
Mean paternal age, years (±SD)
Mean last recorded maternal weight prior to blood draw, lb (±SD)
Cytokine levels measured in maternal serum samples were adjusted for covariates, including gestational age at the time of specimen collection and maternal weight, age, race, ethnicity and country of birth. These adjustments were designed to eliminate variations in cytokine levels related to these factors. Additional file 1 presents the regression results for the potential confounders included in the multivariate models, and Additional file 2 shows the crude unadjusted odds ratios.
Risk associated with a one-unit increase in the natural log-transformed concentration of cytokines and chemokines measured in midpregnancy maternal serum in the Early Markers for Autism studya
ASD mothers vs. GP mothers
ASD mothers vs. DD mothers
DD mothers vs. GP mothers
0.88 to 1.28
0.44 to 1.00
0.95 to 1.73
1.19 to 1.93
0.94 to 2.26
0.99 to 2.05
1.00 to 1.87
0.76 to 2.61
1.00 to 2.72
0.58 to 1.47
0.13 to 1.17
0.42 to 1.62
0.83 to 1.15
0.61 to 1.17
0.81 to 1.32
0.96 to 1.57
0.77 to 2.21
1.12 to 2.64
1.12 to 2.03
0.70 to 2.03
1.24 to 3.85
1.07 to 1.98
0.87 to 3.34
0.72 to 2.18
0.97 to 1.26
0.62 to 1.02
1.01 to 1.48
0.85 to 1.35
0.42 to 1.04
0.93 to 1.74
0.80 to 1.15
0.65 to 1.18
0.91 to 1.51
0.79 to 1.74
0.38 to 1.37
0.65 to 2.42
0.74 to 1.81
0.46 to 1.97
0.39 to 1.27
0.75 to 1.50
0.45 to 1.53
0.75 to 1.77
0.94 to 1.31
0.61 to 1.23
0.86 to 1.41
0.93 to 1.30
0.53 to 1.17
0.89 to 1.52
0.65 to 1.31
0.44 to 2.14
0.55 to 1.76
Pearson correlation coefficients of cytokines measured in maternal midpregnancy serum in the Early Markers for Autism studya
ASD (N= 84
ASD regression (N= 17)
Early-onset ASD (N= 64)
ASD with ID (N= 34)
ASD without ID (N= 30)
DD (N= 49)
GP (N= 159)
Cytokines elevated in ASD
IFN-γ and IL-4
IFN-γ and IL-5
IL-4 and IL-5
Cytokines elevated in DD
IL-2 and IL-4
IL-2 and IL-6
IL-4 and IL-6
In the present study, we characterized levels of cytokines and chemokines in archived maternal serum collected during midpregnancy and analyzed whether these levels were related to ASD and DD outcomes in the child. We have provided evidence for increased IL-4, IL-5 and IFN-γ in mothers bearing a child with ASD. In contrast, mothers bearing a child with DD but not ASD demonstrated increased levels of the cytokines IL-2, IL-4, IL-6 and GM-CSF as well as the chemokine MIP-1α. These contrasting immune profiles described in the ASD and DD groups indicate that different maternal immune profiles during pregnancy may be linked to divergent neurodevelopmental outcomes in the child. The results from both the ASD and DD groups suggest possible elevation in IL-10 relative to the GP controls. This finding is interesting, given that IL-10 is an immunomodulatory cytokine that may be expressed to counteract the effects of inflammatory cytokines.
Maternal immune activity downregulated during pregnancy
The maternal immune system is uniquely regulated during pregnancy to optimize the gestational environment of the fetus . Primarily, it must be poised to protect the mother and fetus from pathogens and other potentially harmful environmental factors. Simultaneously, robust maternal cellular immune responses must be suppressed to avoid rejection of the fetus as a foreign allograft . Evidence suggests that under normal circumstances, pregnancy shifts the maternal immune system toward a more tolerant, low inflammatory state that involves decreased production of cytokines such as IL-6 and IFN-γ and increased production of the more regulatory cytokines, including IL-4, IL-5 and IL-10 [26–29]. Mothers of children with ASD and DD demonstrated increased levels of the inflammatory cytokines IFN-γ and IL-6, respectively, which may be indicative of an atypical immune state during gestation.
Proper maternal immune regulation is important for healthy fetal development
Dramatic changes in maternal immune homeostasis during pregnancy (in response to infection, disease or other environmental influences) are associated with complications such as miscarriage, preterm delivery and preeclampsia . Maternal immune responses can also affect the development of the fetal nervous system [31, 32]. Epidemiological studies have suggested that prenatal infections may be related to neurological disorders such as schizophrenia and autism [33, 34]. Furthermore, animal models have repeatedly demonstrated that robust maternal immune responses during pregnancy can alter offspring behavior and brain histopathology [17, 19, 35–37]. Various cytokines, including IL-6 and IL-2, have been shown to mediate some of these effects [18, 20, 21]. We suggest that atypical maternal immune function during pregnancy may be related to ASD or DD outcomes among children.
Mothers bearing a child with ASD had increased levels of IFN- γ, IL-4 and IL-5
In the current study, mothers bearing a child with ASD had significantly increased levels of serum IFN-γ, IL-4 and IL-5. IFN-γ, the most dramatically elevated cytokine in this population, is involved in aspects of defense against intracellular pathogens, tumor surveillance, autoimmunity, allergy and pregnancy. Peripheral IFN-γ levels are low in healthy pregnancies, and increased production of peripheral IFN-γ is often related to complications such as preeclampsia . IFN-γ is produced by a subset of activated T cells, though its primary source is natural killer (NK) cells. During pregnancy, a unique population of IFN-γ-producing NK cells accumulates in the uterus, where they have a vital role in placental development . The increased levels of serum IFN-γ observed in mothers bearing a child with ASD may be indicative of imbalanced immune function at the maternal-fetal interface, which could lead to improper placental formation and thereby incomplete support of fetal development. Alternatively, increased serum IFN-γ may be due to peripheral immune activity, including a response to infection, or to an immune-mediated disorder. Interestingly, a recent examination of archived neonatal blood spots from children with ASD revealed no elevation in pathogen-specific immunoglobulin G (IgG) levels relative to controls, suggesting that prenatal infection may not be involved .
Epidemiological data previously reported by our group indicated a higher prevalence of allergy and asthma during pregnancy in mothers of children with ASD . That 2005 study examined physician-diagnosed medical conditions in over 2,500 women enrolled in the Kaiser Permanente Medical Care Program. Interestingly, the midpregnancy cytokine profile we describe in the ASD group in the present study (increased IL-4, IL-5 and IFN-γ) may be consistent with an allergic asthma clinical phenotype [41–44]. While IL-4 and IL-5 are known to be upregulated in allergic asthma, IFN-γ is generally thought to be downregulated . However, several reports have shown increased production of IFN-γ in addition to IL-4 and IL-5 in allergic asthma [41–44]. This has also been observed during pregnancy in women with asthma, when higher levels of IFN-γ correlated with worsening maternal and fetal health . Future studies should address the impact of prenatal allergy and asthma on fetal neurodevelopment and further explore the possible connection to behavioral disorders.
Alternative cytokine profile in mothers bearing a child with a developmental delay
We noted that mothers bearing a child with DD but not ASD demonstrated a different midgestational immune profile. The risk of DD was associated with higher levels of the cytokines IL-2, IL-4 and IL-6. Interestingly, IL-6 is part of a cytokine family with well-defined neurological impacts . Extensive evidence links prenatal immune responses involving increased production of inflammatory cytokines such as IL-6 to pregnancy complications and neurological abnormalities among offspring [30, 47]. Mouse models have shown that prenatal exposure to IL-6 or mimics of infectious agents such as LPS or poly(I:C) can induce behavioral changes and brain abnormalities among offspring [18, 19, 21, 48]. Similarly, prenatal exposure to high levels of IL-2 has been shown to induce behavioral differences in murine models . On the basis of these animal studies, it has been suggested that prenatal exposure to these inflammatory conditions may be relevant to the development of autism [20, 48]. However, our results showed elevated IL-6 and IL-2 in mothers bearing a child with DD but not autism. Therefore, we propose that elevated levels of these cytokines have a global effect on neurodevelopment, resulting in cognitive impairment but not necessarily autism.
Maternal cytokines and fetal neurodevelopment
The mechanism by which maternal cytokines affect fetal neurodevelopment is unclear, though the central nervous system (CNS) and immune system interact extensively during fetal development and throughout life. Neuroimmune cross-talk is facilitated by shared signaling pathways and commingling of cellular and soluble components from each system [49, 50]. Evidence suggests that immune components such as cytokines can affect aspects of neurogenesis, neuronal migration and synaptic plasticity, depending on the timing and level of exposure [46, 51, 52]. The developing CNS is especially vulnerable to immunological and environmental influences because the fetus has an immature blood-brain barrier and limited capacity for detoxification and excretion . Under normal circumstances, the placenta forms a barrier between the maternal and fetal circulation, though some maternal immune factors, including IgG and IL-6, are permitted to cross the placenta [22, 54, 55]. When passage of maternal immune components is blocked, the placenta may respond to entities at the maternal-fetal interface and alter the fetal compartment . For example, IFN-γ is not known to pass between the maternal and fetal circulation, though IFN-γ and its receptors are expressed by maternal and fetal cells at the maternal-fetal interface . Therefore, maternal immune components can interact with fetal development both directly and indirectly. The specific neurodevelopmental impact of the different cytokine profiles observed in the present study remains to be determined.
Although our study provides valuable, temporally relevant information regarding prenatal immune status and the child's developmental outcome, a few primary limitations must be considered. First, immune activation in the peripheral blood is not necessarily representative of immune activity at the maternal-fetal interface. Examination of more spatially relevant immune parameters would require placental or amniotic specimens, which were not available in this study. Despite this limitation, the archived serum samples examined provide valuable insight into global maternal immune status during a developmentally relevant window. Second, this study is cross-sectional, as the serum specimens represent a single time point between 15 and 19 weeks of gestation. Maternal immune activity is likely to change throughout pregnancy, and the gestational immune environment outside 15 to 19 weeks' gestation is also developmentally relevant. Future longitudinal studies will provide a more complete picture of the relationship between maternal immune activation throughout pregnancy and fetal neurodevelopment. Third, data regarding the occurrence of infection, allergy and asthma were not available for the population included in this study, so the factors underlying the observed cytokine profiles are unknown. Replication studies are required to further verify the findings described herein. Fourth, it should be noted that the study groups were matched on the basis of child characteristics rather than maternal characteristics. However, two of the three offspring characteristics used for matching, birth month and birth year, relate directly to an important characteristic of the mother (that is, season during midpregnancy) that may influence cytokine levels through their association with seasonal illness. While the remaining covariates were adjusted for in multivariable logistic regression analysis, there is a possibility that our results could be biased because of residual confounding. Finally, diagnoses were made on the basis of medical record abstraction rather than via direct assessment. While we are confident in the consistency and accuracy of our expert medical record review, we recognize that this approach is likely to introduce some level of error, in part because of the differences in the amount and specificity of documentation in the medical records. Our future analyses will involve direct observation and diagnosis of subjects.
In conclusion, we describe different midgestational immune profiles in mothers bearing children with ASD and mothers bearing children with DD. Mothers bearing children with autism had cytokine profiles that may be consistent with an allergy and/or asthma immune phenotype, while mothers bearing children with DD but not autism demonstrated a more inflammatory phenotype. Cytokines and other immune components are known to affect the health of pregnancy and can influence fetal neurodevelopment. The possibility that divergent maternal immune profiles during pregnancy have different effects on fetal neurodevelopment warrants further investigation.
autism spectrum disorder
central nervous system
Department of Developmental Services
Early Markers for Autism
granulocyte macrophage colony-stimulating factor
limit of detection
macrophage inflammatory protein
The authors acknowledge the California Department of Developmental Services and the Orange County Regional Center for help in ascertaining ASD and DD cases. Further acknowledgements include Daniel Najjar for his contribution to data management and analysis, Jack Collins for his role in project management and Bruce Fireman for statistical consultation. Live birth data were provided by the California Center for Health Statistics. Banked specimens and record linkage services were provided by the Sequoia Foundation and Project Baby's Breath (M Kharrazi and GN DeLorenze, Co-Principal Investigators [Co-PIs]) under the direction of the California Genetic Disease Screening Program. The analyses, interpretations and conclusions described in this article are attributable to the authors and not to the California Department of Public Health, the Center for Health Statistics or the Genetic Disease Screening Program. Funding was provided by grants from the National Alliance for Autism Research (824/LC/01-201-004-00-00; LA Croen, PI), the California Tobacco-Related Disease Research Program (8RT-0115; M Kharrazi, PI) and National Institute of Environmental Health Sciences grant 1 P01 ES11269-01, by the US Environmental Protection Agency through the Science to Achieve Results (STAR) program (grant R829388; J Van de Water, PI). The project was also supported by Award Number R01 MH072565 from the National Institute of Mental Health (LA Croen, PI). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health.
- American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 1994, Washington, DC: American Psychiatric Association, 4
- Lord C, Pickles A, McLennan J, Rutter M, Bregman J, Folstein S, Fombonne E, Leboyer M, Minshew N: Diagnosing autism: analyses of data from the Autism Diagnostic Interview. J Autism Dev Disord. 1997, 27: 501-517. 10.1023/A:1025873925661.View ArticlePubMed
- Lord C, Risi S, Lambrecht L, Cook EH, Leventhal BL, DiLavore PC, Pickles A, Rutter M: The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000, 30: 205-223. 10.1023/A:1005592401947.View ArticlePubMed
- Pardo CA, Eberhart CG: The neurobiology of autism. Brain Pathol. 2007, 17: 434-447. 10.1111/j.1750-3639.2007.00102.x.View ArticlePubMed
- Kogan MD, Blumberg SJ, Schieve LA, Boyle CA, Perrin JM, Ghandour RM, Singh GK, Strickland BB, Trevathan E, van Dyck PC: Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics. 2009, 124: 1395-1403. 10.1542/peds.2009-1522.View ArticlePubMed
- Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators, Centers for Disease Control and Prevention (CDC): Prevalence of autism spectrum disorders: Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ. 2009, 58: 1-20.
- Jonakait GM: The effects of maternal inflammation on neuronal development: possible mechanisms. Int J Dev Neurosci. 2007, 25: 415-425. 10.1016/j.ijdevneu.2007.08.017.View ArticlePubMed
- Ashwood P, Wills S, Van de Water J: The immune response in autism: a new frontier for autism research. J Leukoc Biol. 2006, 80: 1-15. 10.1189/jlb.1205707.View ArticlePubMed
- Money J, Bobrow NA, Clarke FC: Autism and autoimmune disease: a family study. J Autism Child Schizophr. 1971, 1: 146-160. 10.1007/BF01537954.View ArticlePubMed
- Sweeten TL, Bowyer SL, Posey DJ, Halberstadt GM, McDougle CJ: Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics. 2003, 112: e420-10.1542/peds.112.5.e420.View ArticlePubMed
- Croen LA, Grether JK, Yoshida CK, Odouli R, Van de Water J: Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr Adolesc Med. 2005, 159: 151-157. 10.1001/archpedi.159.2.151.View ArticlePubMed
- Martin LA, Ashwood P, Braunschweig D, Cabanlit M, Van de Water J, Amaral DG: Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav Immun. 2008, 22: 806-816. 10.1016/j.bbi.2007.12.007.PubMed CentralView ArticlePubMed
- Singer HS, Morris CM, Gause CD, Gillin PK, Crawford S, Zimmerman AW: Antibodies against fetal brain in sera of mothers with autistic children. J Neuroimmunol. 2008, 194: 165-172. 10.1016/j.jneuroim.2007.11.004.View ArticlePubMed
- Zimmerman AW, Connors SL, Matteson KJ, Lee LC, Singer HS, Castaneda JA, Pearce DA: Maternal antibrain antibodies in autism. Brain Behav Immun. 2007, 21: 351-357. 10.1016/j.bbi.2006.08.005.View ArticlePubMed
- Croen LA, Braunschweig D, Haapanen L, Yoshida CK, Fireman B, Grether JK, Kharrazi M, Hansen RL, Ashwood P, Van de Water J: Maternal mid-pregnancy autoantibodies to fetal brain protein: the early markers for autism study. Biol Psychiatry. 2008, 64: 583-588. 10.1016/j.biopsych.2008.05.006.PubMed CentralView ArticlePubMed
- Meyer U, Feldon J, Schedlowski M, Yee BK: Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev. 2005, 29: 913-947. 10.1016/j.neubiorev.2004.10.012.View ArticlePubMed
- Shi L, Fatemi SH, Sidwell RW, Patterson PH: Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci. 2003, 23: 297-302.PubMed
- Ashdown H, Dumont Y, Ng M, Poole S, Boksa P, Luheshi GN: The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia. Mol Psychiatry. 2006, 11: 47-55. 10.1038/sj.mp.4001748.View ArticlePubMed
- Smith SE, Li J, Garbett K, Mirnics K, Patterson PH: Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci. 2007, 27: 10695-10702. 10.1523/JNEUROSCI.2178-07.2007.PubMed CentralView ArticlePubMed
- Ponzio NM, Servatius R, Beck K, Marzouk A, Kreider T: Cytokine levels during pregnancy influence immunological profiles and neurobehavioral patterns of the offspring. Ann N Y Acad Sci. 2007, 1107: 118-128. 10.1196/annals.1381.013.View ArticlePubMed
- Samuelsson AM, Jennische E, Hansson HA, Holmäng A: Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABAA dysregulation and impaired spatial learning. Am J Physiol Regul Integr Comp Physiol. 2006, 290: R1345-R1356.View ArticlePubMed
- Zaretsky MV, Alexander JM, Byrd W, Bawdon RE: Transfer of inflammatory cytokines across the placenta. Obstet Gynecol. 2004, 103: 546-550. 10.1097/01.AOG.0000114980.40445.83.View ArticlePubMed
- Yeargin-Allsopp M, Rice C, Karapurkar T, Doernberg N, Boyle C, Murphy C: Prevalence of autism in a US metropolitan area. JAMA. 2003, 289: 49-55. 10.1001/jama.289.1.49.View ArticlePubMed
- Palmer GW, Claman HN: Pregnancy and immunology: selected aspects. Ann Allergy Asthma Immunol. 2002, 89: 350-360. 10.1016/S1081-1206(10)62034-0. 428View ArticlePubMed
- Trowsdale J, Betz AG: Mother's little helpers: mechanisms of maternal-fetal tolerance. Nat Immunol. 2006, 7: 241-246.View ArticlePubMed
- Denney JM, Nelson EL, Wadhwa PD, Waters TP, Mathew L, Chung EK, Goldenberg RL, Culhane JF: Longitudinal modulation of immune system cytokine profile during pregnancy. Cytokine. 2011, 53: 170-177. 10.1016/j.cyto.2010.11.005.PubMed CentralView ArticlePubMed
- Curry AE, Vogel I, Skogstrand K, Drews C, Schendel DE, Flanders WD, Hougaard DM, Thorsen P: Maternal plasma cytokines in early- and mid-gestation of normal human pregnancy and their association with maternal factors. J Reprod Immunol. 2008, 77: 152-160. 10.1016/j.jri.2007.06.051.View ArticlePubMed
- Wegmann TG, Lin H, Guilbert L, Mosmann TR: Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?. Immunol Today. 1993, 14: 353-356. 10.1016/0167-5699(93)90235-D.View ArticlePubMed
- Szekeres-Bartho J, Halasz M, Palkovics T: Progesterone in pregnancy; receptor-ligand interaction and signaling pathways. J Reprod Immunol. 2009, 83: 60-64. 10.1016/j.jri.2009.06.262.View ArticlePubMed
- Raghupathy R, Kalinka J: Cytokine imbalance in pregnancy complications and its modulation. Front Biosci. 2008, 13: 985-994. 10.2741/2737.View ArticlePubMed
- Coe CL, Lubach GR: Prenatal origins of individual variation in behavior and immunity. Neurosci Biobehav Rev. 2005, 29: 39-49. 10.1016/j.neubiorev.2004.11.003.View ArticlePubMed
- Meyer U, Yee BK, Feldon J: The neurodevelopmental impact of prenatal infections at different times of pregnancy: the earlier the worse?. Neuroscientist. 2007, 13: 241-256. 10.1177/1073858406296401.View ArticlePubMed
- Brown AS, Derkits EJ: Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry. 2010, 167: 261-280. 10.1176/appi.ajp.2009.09030361.PubMed CentralView ArticlePubMed
- Atladóttir HO, Thorsen P, Østergaard L, Schendel DE, Lemcke S, Abdallah M, Parner ET: Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. J Autism Dev Disord. 2010, 40: 1423-1430. 10.1007/s10803-010-1006-y.View ArticlePubMed
- Shi L, Smith SE, Malkova N, Tse D, Su Y, Patterson PH: Activation of the maternal immune system alters cerebellar development in the offspring. Brain Behav Immun. 2009, 23: 116-123. 10.1016/j.bbi.2008.07.012.PubMed CentralView ArticlePubMed
- Golan HM, Lev V, Hallak M, Sorokin Y, Huleihel M: Specific neurodevelopmental damage in mice offspring following maternal inflammation during pregnancy. Neuropharmacology. 2005, 48: 903-917. 10.1016/j.neuropharm.2004.12.023.View ArticlePubMed
- Gilmore JH, Jarskog LF, Vadlamudi S: Maternal poly I:C exposure during pregnancy regulates TNFα, BDNF, and NGF expression in neonatal brain and the maternal-fetal unit of the rat. J Neuroimmunol. 2005, 159: 106-112. 10.1016/j.jneuroim.2004.10.008.View ArticlePubMed
- Laresgoiti-Servitje E, Gómez-López N, Olson DM: An immunological insight into the origins of pre-eclampsia. Hum Reprod Update. 2010, 16: 510-524. 10.1093/humupd/dmq007.View ArticlePubMed
- Lash GE, Robson SC, Bulmer JN: Review: Functional role of uterine natural killer (uNK) cells in human early pregnancy decidua. Placenta. 2010, 31 Suppl: S87-S92.View ArticlePubMed
- Grether JK, Croen LA, Anderson MC, Nelson KB, Yolken RH: Neonatally measured immunoglobulins and risk of autism. Autism Res. 2010, 3: 323-332. 10.1002/aur.160.View ArticlePubMed
- Cho SH, Stanciu LA, Holgate ST, Johnston SL: Increased interleukin-4, interleukin-5, and interferon-γ in airway CD4+ and CD8+ T cells in atopic asthma. Am J Respir Crit Care Med. 2005, 171: 224-230.View ArticlePubMed
- Magnan AO, Mély LG, Camilla CA, Badier MM, Montero-Julian FA, Guillot CM, Casano BB, Prato SJ, Fert V, Bongrand P, Vervloet D: Assessment of the Th1/Th2 paradigm in whole blood in atopy and asthma: increased IFN-γ-producing CD8+ T cells in asthma. Am J Respir Crit Care Med. 2000, 161: 1790-1796.View ArticlePubMed
- Tamási L, Bohács A, Pállinger E, Falus A, Rigó J, Müller V, Komlósi Z, Magyar P, Losonczy G: Increased interferon-γ- and interleukin-4-synthesizing subsets of circulating T lymphocytes in pregnant asthmatics. Clin Exp Allergy. 2005, 35: 1197-1203. 10.1111/j.1365-2222.2005.02322.x.View ArticlePubMed
- Kumar RK, Webb DC, Herbert C, Foster PS: Interferon-γ as a possible target in chronic asthma. Inflamm Allergy Drug Targets. 2006, 5: 253-256. 10.2174/187152806779010909.View ArticlePubMed
- Ngoc PL, Gold DR, Tzianabos AO, Weiss ST, Celedón JC: Cytokines, allergy, and asthma. Curr Opin Allergy Clin Immunol. 2005, 5: 161-166. 10.1097/01.all.0000162309.97480.45.View ArticlePubMed
- Bauer S, Kerr BJ, Patterson PH: The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci. 2007, 8: 221-232.View ArticlePubMed
- Boksa P: Effects of prenatal infection on brain development and behavior: a review of findings from animal models. Brain Behav Immun. 2010, 24: 881-897. 10.1016/j.bbi.2010.03.005.View ArticlePubMed
- Patterson PH: Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res. 2009, 204: 313-321. 10.1016/j.bbr.2008.12.016.View ArticlePubMed
- Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC: CNS immune privilege: hiding in plain sight. Immunol Rev. 2006, 213: 48-65. 10.1111/j.1600-065X.2006.00441.x.PubMed CentralView ArticlePubMed
- Fricchione G, Daly R, Rogers MP, Stefano GB: Neuroimmunologic influences in neuropsychiatric and psychophysiologic disorders. Acta Pharmacol Sin. 2001, 22: 577-587.PubMed
- Zhu Y, Yu T, Zhang XC, Nagasawa T, Wu JY, Rao Y: Role of the chemokine SDF-1 as the meningeal attractant for embryonic cerebellar neurons. Nat Neurosci. 2002, 5: 719-720.PubMed CentralView ArticlePubMed
- Rostene W, Kitabgi P, Parsadaniantz SM: Chemokines: a new class of neuromodulator?. Nat Rev Neurosci. 2007, 8: 895-903. 10.1038/nrn2255.View ArticlePubMed
- Bondy SC, Campbell A: Developmental neurotoxicology. J Neurosci Res. 2005, 81: 605-612. 10.1002/jnr.20589.View ArticlePubMed
- Myren M, Mose T, Mathiesen L, Knudsen LE: The human placenta: an alternative for studying foetal exposure. Toxicol In Vitro. 2007, 21: 1332-1340. 10.1016/j.tiv.2007.05.011.View ArticlePubMed
- Simister NE: Placental transport of immunoglobulin G. Vaccine. 2003, 21: 3365-3369. 10.1016/S0264-410X(03)00334-7.View ArticlePubMed
- Hauguel-de Mouzon S, Guerre-Millo M: The placenta cytokine network and inflammatory signals. Placenta. 2006, 27: 794-798. 10.1016/j.placenta.2005.08.009.View ArticlePubMed
- Murphy SP, Tayade C, Ashkar AA, Hatta K, Zhang J, Croy BA: Interferon γ in successful pregnancies. Biol Reprod. 2009, 80: 848-859. 10.1095/biolreprod.108.073353.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.